Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378576315> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4378576315 abstract "Hypoproliferative anemia is a frequently encountered adverse event in cancer patients receiving immune checkpoint inhibitors (ICI). Secondary pure red cell aplasia (PRCA) is a rare but recognized immune related adverse event. With the burgeoning use of ICIs, the association of secondary PRCA with an underlying lymphoproliferative disorder is often overlooked.We report a case of a 67-year-old non-Hispanic Caucasian male with metastatic castrate resistant prostate cancer, who developed severe transfusion dependent anemia with reticulocytopenia while receiving treatment with olaparib and pembrolizumab. His bone marrow findings demonstrated erythroid hypoplasia, in addition to a CD5-negative, CD10-negative monotypic B-cell population and a somatic MYD88L265P mutation. With a presence of an IgM-paraprotein, he was diagnosed with Waldenström macroglobulinemia (WM) with secondary PRCA and treated with 6 cycles of bendamustine and rituximab. He achieved a complete response with this regimen and was transfusion independent.In this case, underlying WM was uncovered through systematic investigation of anemia caused by ICI therapy. This report highlights the possibility of a lymphoproliferative disorder in patients with concerns for PRCA with prior ICI exposure. If identified, treating the underlying lymphoproliferative disorder is highly efficacious in the management of the secondary PRCA." @default.
- W4378576315 created "2023-05-28" @default.
- W4378576315 creator A5011907185 @default.
- W4378576315 creator A5045281097 @default.
- W4378576315 creator A5069673407 @default.
- W4378576315 creator A5073891310 @default.
- W4378576315 date "2023-05-28" @default.
- W4378576315 modified "2023-10-16" @default.
- W4378576315 title "Waldenström macroglobulinemia with secondary pure red cell aplasia in a patient with metastatic castrate resistant prostate cancer receiving an immune checkpoint inhibitor: a case report" @default.
- W4378576315 cites W1974399207 @default.
- W4378576315 cites W2027219476 @default.
- W4378576315 cites W2129199033 @default.
- W4378576315 cites W2131263737 @default.
- W4378576315 cites W2140380015 @default.
- W4378576315 cites W2145428758 @default.
- W4378576315 cites W2339896950 @default.
- W4378576315 cites W2549097307 @default.
- W4378576315 cites W2751679635 @default.
- W4378576315 cites W2805689516 @default.
- W4378576315 cites W2902703786 @default.
- W4378576315 cites W2917423789 @default.
- W4378576315 cites W2955877427 @default.
- W4378576315 cites W2973917985 @default.
- W4378576315 cites W2990557229 @default.
- W4378576315 cites W3014279612 @default.
- W4378576315 cites W3023301242 @default.
- W4378576315 cites W3082288029 @default.
- W4378576315 doi "https://doi.org/10.1186/s13256-023-03948-4" @default.
- W4378576315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37245043" @default.
- W4378576315 hasPublicationYear "2023" @default.
- W4378576315 type Work @default.
- W4378576315 citedByCount "1" @default.
- W4378576315 countsByYear W43785763152023 @default.
- W4378576315 crossrefType "journal-article" @default.
- W4378576315 hasAuthorship W4378576315A5011907185 @default.
- W4378576315 hasAuthorship W4378576315A5045281097 @default.
- W4378576315 hasAuthorship W4378576315A5069673407 @default.
- W4378576315 hasAuthorship W4378576315A5073891310 @default.
- W4378576315 hasBestOaLocation W43785763151 @default.
- W4378576315 hasConcept C121608353 @default.
- W4378576315 hasConcept C126322002 @default.
- W4378576315 hasConcept C143998085 @default.
- W4378576315 hasConcept C197934379 @default.
- W4378576315 hasConcept C203014093 @default.
- W4378576315 hasConcept C2777422296 @default.
- W4378576315 hasConcept C2778248108 @default.
- W4378576315 hasConcept C2779338263 @default.
- W4378576315 hasConcept C2780192828 @default.
- W4378576315 hasConcept C2780653079 @default.
- W4378576315 hasConcept C2781442060 @default.
- W4378576315 hasConcept C71924100 @default.
- W4378576315 hasConceptScore W4378576315C121608353 @default.
- W4378576315 hasConceptScore W4378576315C126322002 @default.
- W4378576315 hasConceptScore W4378576315C143998085 @default.
- W4378576315 hasConceptScore W4378576315C197934379 @default.
- W4378576315 hasConceptScore W4378576315C203014093 @default.
- W4378576315 hasConceptScore W4378576315C2777422296 @default.
- W4378576315 hasConceptScore W4378576315C2778248108 @default.
- W4378576315 hasConceptScore W4378576315C2779338263 @default.
- W4378576315 hasConceptScore W4378576315C2780192828 @default.
- W4378576315 hasConceptScore W4378576315C2780653079 @default.
- W4378576315 hasConceptScore W4378576315C2781442060 @default.
- W4378576315 hasConceptScore W4378576315C71924100 @default.
- W4378576315 hasIssue "1" @default.
- W4378576315 hasLocation W43785763151 @default.
- W4378576315 hasLocation W43785763152 @default.
- W4378576315 hasOpenAccess W4378576315 @default.
- W4378576315 hasPrimaryLocation W43785763151 @default.
- W4378576315 hasRelatedWork W2011737681 @default.
- W4378576315 hasRelatedWork W2015099005 @default.
- W4378576315 hasRelatedWork W2166237712 @default.
- W4378576315 hasRelatedWork W2593775314 @default.
- W4378576315 hasRelatedWork W2620106135 @default.
- W4378576315 hasRelatedWork W2885867084 @default.
- W4378576315 hasRelatedWork W2971092198 @default.
- W4378576315 hasRelatedWork W2980742945 @default.
- W4378576315 hasRelatedWork W3036624213 @default.
- W4378576315 hasRelatedWork W2520389308 @default.
- W4378576315 hasVolume "17" @default.
- W4378576315 isParatext "false" @default.
- W4378576315 isRetracted "false" @default.
- W4378576315 workType "article" @default.